BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $252.14, but opened at $269.30. BeOne Medicines shares last traded at $267.14, with a volume of 127,226 shares traded.
Analyst Ratings Changes
A number of analysts have recently weighed in on ONC shares. TD Securities reaffirmed a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research report on Thursday, April 24th. Morgan Stanley upped their price target on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research note on Friday, June 27th. Guggenheim upped their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut shares of BeOne Medicines from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, JPMorgan Chase & Co. increased their price objective on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $327.56.
View Our Latest Stock Report on BeOne Medicines
BeOne Medicines Trading Up 1.4%
The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The business's fifty day moving average is $249.71.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. As a group, equities research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.
Insider Activity at BeOne Medicines
In related news, COO Xiaobin Wu sold 1,934 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $253.15, for a total value of $489,592.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $223.50, for a total value of $9,333,360.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 137,573 shares of company stock valued at $34,156,799. 6.62% of the stock is owned by corporate insiders.
Institutional Trading of BeOne Medicines
A number of institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines during the second quarter worth $39,000. Signaturefd LLC bought a new stake in shares of BeOne Medicines in the second quarter valued at about $49,000. Parallel Advisors LLC bought a new stake in shares of BeOne Medicines in the second quarter valued at about $59,000. Avanza Fonder AB bought a new stake in shares of BeOne Medicines in the second quarter valued at about $199,000. Finally, Aaron Wealth Advisors LLC bought a new stake in shares of BeOne Medicines in the second quarter valued at about $200,000. 48.55% of the stock is currently owned by institutional investors.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access